General Clinical Chemistry Analyzers and Accessories
Abcam Adaphostin, 5MG
MW 393.5 Da, Purity >=98%. Adaphostin is a p210bcr/abl tyrosine kinase inhibitor (IC50 = 14 μM) that displays anti-proliferative activity in leukemia models, human prostate cancer cell line PC-3 and other cancer cell lines. Adaphostin is a potent inducer of myeloid cell death.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BAY-299, TAF1 and BRD1 inhibitor, 10MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BAY-299, TAF1 and BRD1 inhibitor, 1MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Binimetinib, MEK1/2 inhibitor, 25MG
MW 441.2 Da, Purity >99%. Potent and selective allosteric inhibitor of MEK1/2. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 50MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WAY-316606, 5MG
MW 448.5 Da, Purity >=98%. A secreted Frizzled-Related Protein-1 (sFRP-1) inhibitor (IC₅₀ = 0.65 μM). It blocks sFRP-1 from interacting with Wnt and thus increases Wnt signaling.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK-690693 hydrochloride, ATP-competitive pan-Akt kinase inhibitor, 25MG
MW 425.5 Da, Purity >99%. Novel ATP-competitive pan-Akt kinase inhibitor (IC₅₀ values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively). Also exhibits some inhibition of AMPK, PKA and PAK and PKC isoforms (IC₅₀ < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.
The product is subject to the following: Abcam Restricted Use Statement
AdipoGen AVG-Cl
Chemical. CAS 55720-26-8. Formula C6H12N2O3 . HCl. MW 196.63. Synthetic. Potent inhibitor of ethylene synthesis in plants acting at the level of 1-aminocyclopropanecarboxylic acid synthase.
Abcam FC 131, C x CR4 activation inhibitor, 5MG
MW 729.8 Da, Purity >95%. FC 131, CXCR4 activation inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
AdipoGen Flumequine
Chemical. CAS 42835-25-6. Formula C14H12FNO3. MW 261.3. Synthetic. Flumequine is a fluoroquinolone synthetic chemotherapeutic antibiotic used to treat bacterial infections. Targets primarily gram negative bacteria, especially those which cause enteric infections in animals. It is used to study processes that affect mammalian chromosome and DNA unwinding at the level of gyrase/topoisomerases. It inhibits topoisomerases, which are needed for the transcription and replication of bacterial DNA. The inhibition of the topoisomerases results in strand breakage of the bacterial chromosome, supercoiling and resealing. Therefore, DNA replication and transcription is inhibited. It was also used to study hepatocarcinogenicity and DNA damage in mice and the mechanisms of quinolone resistance.
Abcam D-Gluconic acid, methyl ester, 50MG
MW 210.18 g/mol. Membrane permeant analog of D-gluconic acid. Useful as a component of cell culture media; enzymatic degradation of xylan and glucomannan; various pharmaceutical preparations; as well as an intermediate in carbohydrate based synthetic preparations of sugar derivatives.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IWP-4, 50MG
MW 496.6 Da, Purity >98%. Potent inhibitor of Wnt pathway regulatory protein porupine (Porcn). Blocks Wnt protein secretion and prevents the canonical and non-canonical signaling pathways. Blocks palmitylation, and subsquent secretion and activity of Wnt. Induces differentiation of cardiomyocytes from human ESCs and iPSCs.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD1480, 10MG
MW 348.76 Da, Purity >98%. Novel, potent and selective small-molecule JAK2 inhibitor (IC₅₀ < 3 nM). It can effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in stromal cells as well as tumor cells. Also demonstrates >50-fold selectivity for JAK2 over JAK3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TW-37, 25MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 5MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement